10:37 AM EDT, 07/28/2025 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Monday its phase 1b trial of DehydraTECH oral drug delivery technology showed that it reduced overall side effects by 36.5% compared with the Rybelsus control arm.

The eight-week trial also showed that the drug delivery technology reduced gastrointestinal side effects by 43.5% compared with the control arm, the company said.

Further results and all final data, including additional safety, tolerability and efficacy parameter assessments, will be available near the end of the year, Lexaria said.

Price: 0.91, Change: -0.07, Percent Change: -7.26